Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg Tid in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg Tid in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET-2
  • Sponsors Bausch Health Companies; Salix Pharmaceuticals

    • Most Recent Events

    • 23 May 2021 Results (n=3837) of pooled post hoc analysis of assessing efficacy of 3 Phase III studies TARGET-1, TARGET-2 and TARGET-3, presented at the Digestive Disease Week 2021.
    • 23 May 2021 Results (n=1258) of post-hoc pooled analysis from two phase 3 studies assessing efficacy of rifaximin in improving both abdominal pain and bloating in patients with IBS-D presented at the Digestive Disease Week 2021
    • 17 May 2021 According to a Salix Pharma media release, results of pooled post hoc analysis will be presented at Digestive Disease Week (DDW) 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top